InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,002.80
(
0.00%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.63
(
0.07%
)
Bitcoin
66,620.99
(
0.32%
)
Post# of 251581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119467
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 214252

Friday, 10/20/2017 8:54:11 PM

Friday, October 20, 2017 8:54:11 PM

Post# of 251581
ATRS receives CRL for Xyosted:

https://finance.yahoo.com/news/antares-pharma-receives-complete-response-224917144.html

The CRL identified two deficiencies related to clinical data. Based on findings in studies...the FDA is concerned that XYOSTED could cause a clinically meaningful increase in blood pressure. In addition, the letter also raised a concern regarding the occurrence of depression and suicidality.

Ouch.

The stock is down only 9%/AH because ATRS pre-announced the expected CRL last week (#msg-135361392).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up